Effect of pertuzumab plus neoadjuvant trastuzumab-based chemotherapy in early-stage HER2-positive breast cancer according to BluePrint molecularly defined breast cancer subtypes

Category Primary study
JournalCancer Research
Year 2022
This article has no abstract
Epistemonikos ID: e3e26ebfa2012fcff0ce12ebdf1eae38a5ee9b27
First added on: Feb 14, 2025